CVM Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (19 Apr 2024 @ 16:00):

Stats
Today's Volume	211 697
Average Volume	315 204
Market Cap	84.21M
EPS	$0 ( 2024-02-13 )
Next earnings date	( $-0.140 ) 2024-05-10
Last Dividend	$0.250 ( 1996-08-28 )
Next Dividend	$0 ( N/A )
P/E	-2.26
ATR14	$0.00600 (0.39%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-29	Talor Eyal	Buy	1 256	Common Stock
2024-03-29	Prichep Patricia B	Buy	2 246	Common Stock
2024-03-29	Kersten Geert R	Buy	2 709	Common Stock
2023-12-29	Talor Eyal	Buy	882	Common Stock
2023-12-29	Prichep Patricia B	Buy	1 577	Common Stock

INSIDER POWER
97.46
Last 100 transactions
Buy: 4 896 616 \| Sell: 99 000

Volume Correlation

Long: 0.23 (neutral)

Short: -0.94 (very strong negative)

Signal:(53.988) Neutral

CEL-SCI Corp Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

CEL-SCI Corp Correlation - Currency/Commodity

0.58
( weak )

0.19
( neutral )

0.00
( neutral )

0.48
( neutral )

0.77
( moderate )

-0.56
( weak negative )

CEL-SCI Corp Financials

Annual	2023
Revenue:	$0
Gross Profit:	$-3.96M (0.00 %)
EPS:	$-0.720

Q4	2023
Revenue:	$0
Gross Profit:	$-998 653 (0.00 %)
EPS:	$-0.160

Q3	2023
Revenue:	$0
Gross Profit:	$-988 942 (0.00 %)
EPS:	$-0.190

Q2	2023
Revenue:	$0
Gross Profit:	$-989 906 (0.00 %)
EPS:	$-0.200

Financial Reports:

No articles found.

CEL-SCI Corp Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

CEL-SCI Corp Dividend Information - No Dividend Player

Dividend Sustainability Score: 0 - N/A | Divividend Growth Potential Score: 0 - N/A

Information

First Dividend	$0.250	1996-08-28
Last Dividend	$0.250	1996-08-28
Next Dividend	$0	N/A
Payout Date	2017-06-15
Next Payout Date	N/A
# dividends	1	--
Total Paid Out	$0.250	--
Avg. Dividend % Per Year	0.00%	--
Score	0.01	--
Div. Sustainability Score	0
Div.Growth Potential Score	0
Div. Directional Score	0	--

Next Divdend (Est)
(2024-04-20)

$0 Estimate 0.00 %

Dividend Stability

0.00 Very Bad

Dividend Score

0.01

Pay Frequency

Insufficient data to determine frequency

Yearly Payout

Year	Amount	Yield

Dividend Commentary

Unable to generate commentary due to missing data.

Top 10 dividend Companies for AMEX

Symbol	Title	Last dividend	Frequency	Yearly Dividend
JZRO	Ex Dividend Junior	2023-06-30	Quarterly	0.00%
RIET	Ex Dividend Junior	2023-09-12	Monthly	0.00%
AIVI	Ex Dividend Junior	2023-06-26	Quarterly	0.00%
EIM	Ex Dividend King	2023-09-21	Monthly	0.00%
IAF	Ex Dividend Junior	2023-08-23	Quarterly	0.00%
PFRL	Ex Dividend Junior	2023-08-01	Monthly	0.00%
DFAT	Ex Dividend Junior	2023-09-19	Quarterly	0.00%
NOG	Ex Dividend Knight	2023-09-27	Quarterly	0.00%
COHN	Ex Dividend Junior	2023-08-17	Semi-Annually	0.00%
GLQ	Ex Dividend Knight	2023-09-21	Monthly	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0	1.500	0	0	[0 - 0.5]
returnOnAssetsTTM	-1.087	1.200	-10.00	-10.00	[0 - 0.3]
returnOnEquityTTM	-2.05	1.500	-10.00	-10.00	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	1.264	0.800	8.68	6.94	[1 - 3]
quickRatioTTM	0.184	0.800	-3.62	-2.90	[0.8 - 2.5]
cashRatioTTM	0.666	1.500	7.41	10.00	[0.2 - 2]
debtRatioTTM	0.456	-1.500	2.40	-3.59	[0 - 0.6]
interestCoverageTTM	-42.08	1.000	-10.00	-10.00	[3 - 30]
operatingCashFlowPerShareTTM	-0.476	2.00	-0.159	-0.317	[0 - 30]
freeCashFlowPerShareTTM	-0.484	2.00	-0.242	-0.484	[0 - 20]
debtEquityRatioTTM	1.035	-1.500	5.86	-8.79	[0 - 2.5]
grossProfitMarginTTM	0	1.000	-3.33	-3.33	[0.2 - 0.8]
operatingProfitMarginTTM	0	1.000	-2.00	-2.00	[0.1 - 0.6]
cashFlowToDebtRatioTTM	-1.761	1.000	-10.00	-10.00	[0.2 - 2]
assetTurnoverTTM	0	0.800	-3.33	-2.67	[0.5 - 2]
Total Score				-2.64

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	-2.59	1.000	-0.363	0	[1 - 100]
returnOnEquityTTM	-2.05	2.50	-10.00	-10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	-0.484	2.00	-0.161	-0.484	[0 - 30]
dividendYielPercentageTTM	0	1.500	0	0	[0 - 0.4]
operatingCashFlowPerShareTTM	-0.476	2.00	-0.159	-0.317	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	-0.0518	1.500	-3.68	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0	1.000	-2.50	0	[0.1 - 0.5]
Total Score				-1.902

CEL-SCI Corp

CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and cancer. The company also develops LEAPS-H1N1-DC; CEL-2000 and CEL-4000 are product candidates for the treatment of rheumatoid arthritis; and LEAPS COV-19, a product candidate to treat COVID-19 coronavirus. CEL-SCI Corporation has a collaboration agreement with the University of Georgia's Center for Vaccines and Immunology to develop LEAPS COVID-19 immunotherapy. The company was incorporated in 1983 and is headquartered in Vienna, Virginia.